Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice.
Growth Factors · 2015
Last updated 2026-05-28In a study on diabetic mice, a GLP-1 drug called exendin-4 (given at 3 micrograms per kilogram) reduced kidney damage in the tubes of the kidneys, not the filtering units. It also lowered blood sugar, reduced markers of cell damage, and decreased inflammation and oxidative stress in the kidneys.
AI summary of the abstract below.
| Journal | Growth Factors, 2015 |
|---|---|
| Citations | 60 |
| Relative citation ratio | 2.18 |
| NIH percentile | 76 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
In this study, we aimed to research the restorative effects of exendin-4, a GLP-1 analog, on renal tubular injury in streptozotocin-induced diabetes model. BALB/c male mice were divided into four groups: non-diabetic, non-diabetic + exendin-4 (3 μg/kg), diabetic and diabetic + exendin-4. In our diabetic model, we observed renal injury mainly in tubular area rather than glomeruli and exendin-4 decreased tubular injury with its glucose lowering effect. Besides, PCNA positive tubular cells, activities of LDH and Na(+)-K(+)-ATPase were also significantly declined by the administration of exendin-4. Furthermore, exendin-4 attenuated the levels of ROS, MDA, 8-OHdG, proinflammatory cytokines (TNF-α, IL-1β), chemokine MCP-1, ICAM-1, and fibrosis-related molecules (transforming growth factor β1 and fibronectin). In consistent with reducing tubular injury, macrophage infiltration and both MCP-1 and ICAM-1 production in tubular cells were decreased. These results indicate that exendin-4 may decrease renal tubular injury seen in the beginning of diabetic nephropathy by decreasing ROS production and inflammation.
Verbatim abstract via PubMed 26728502 ↗